Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Oral chloroquine is the treatment of choice for uncomplicated Plasmodium malariae infections worldwide. We did a prospective 28-day in-vivo assessment of the efficacy of chloroquine for treatment of P malariae on Legundi Island in Lampung Bay, Sumatra, Indonesia. Of 28 patients, one had recurrent parasitaemia on day 28, and two had persistent parasitaemia to day 8. Whole-blood chloroquine and desethylchloroquine concentrations were at ordinarily effective levels (> or = 100 microg/L) on day 8 in both cases of persistent parasitaemia. These findings suggest that clinical resistance to chloroquine by P malariae occurs in the Indonesian archipelago of southeast Asia.

Original publication

DOI

10.1016/S0140-6736(02)09336-4

Type

Journal article

Journal

Lancet

Publication Date

06/07/2002

Volume

360

Pages

58 - 60

Keywords

Adolescent, Adult, Aged, Animals, Antimalarials, Child, Chloroquine, Drug Resistance, Female, Humans, Indonesia, Malaria, Falciparum, Malaria, Vivax, Male, Middle Aged, Plasmodium falciparum, Plasmodium vivax, Polymerase Chain Reaction, Prevalence, Prospective Studies